Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : FDA Denies Merck Request to Block Generic Form of Nasonex

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/19/2012 | 08:47pm CET
   By Peter Loftus 
 

Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.

The U.S. Food and Drug Administration this month denied Merck's petition asking the agency not to approve applications by generic drug makers to sell certain proposed generic forms of Nasonex. Merck, of Whitehouse Station, N.J., had argued the FDA shouldn't approve any proposed generic copy that has a different formulation than Nasonex.

The FDA denial of Merck's petition follows a federal court ruling earlier this year finding that Apotex Corp.'s proposed generic version of Nasonex doesn't violate a Merck patent for the drug. Merck has appealed that patent ruling.

Both developments remove some obstacles to the market entry of competing generic versions of Nasonex before patent protection expires in 2018, which would hurt sales of the branded drug. The drug, which Merck obtained in its 2009 purchase of Schering-Plough, generated $960 million in sales for the first nine months of 2012.

Canada's Apotex wants to sell a generic version of Nasonex that is slightly different from the original. The proposed Apotex product would have the same active ingredient, mometasone furoate, but in a non-water formulation, whereas Merck's product has a water component.

In 2009, Merck filed a patent-infringement lawsuit against Apotex in response to Apotex's application to market the generic product. Apotex argued that its proposed product wouldn't infringe upon Merck's patent because it would be a non-water formulation of mometasone furoate.

Following an April trial in federal court in Trenton, N.J., U.S. District Judge Peter G. Sheridan in June ruled that Apotex's proposed product wouldn't infringe upon the Merck patent, though the judge upheld the patent's validity. Merck has appealed the ruling.

In July, Merck filed a so-called citizen petition asking the FDA to refrain from approving any application for a non-water version of Nasonex that relies upon clinical data for the original drug. Merck argued that the non-water version couldn't be considered as the pharmaceutical equivalent to Nasonex because there would likely be differences in how they are absorbed in the body.

Lawyers for Apotex objected to Merck's request in a November comment letter to FDA, saying there was established precedent for the agency to approve generic versions of branded drugs that contain slightly different forms of the same active ingredient.

In a Dec. 7 letter, the FDA denied Merck's petition, saying that a non-water form of mometasone could potentially be considered pharmaceutically and therapeutically equivalent to the water-based Nasonex, assuming other requirements are met.

"We were disappointed with the decision on the citizen petition," said Merck spokesman Ronald Rogers.

The FDA denial of Merck's petition doesn't amount to approval of Apotex's generic product; that review is pending.

Apotex spokesman Steve Giuli declined to comment.

Merck shares declined 38 cents to $43.85 Wednesday.

Write to Peter Loftus at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
01/19 MERCK AND : These Two Biotechs Just Reported Key Data
01/19 EISAI : and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA®..
01/19 MERCK AND : First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patie..
01/19 MERCK AND : LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of..
01/19 MERCK AND : chalks up another win for Keytruda in lung cancer
01/18 MERCK AND : shares continue to rise after successful lung cancer trial
01/18 MERCK AND : The Consumer Health of Merck Walks the Talk with its WE100 Movement
01/17 MERCK AND : KEYTRUDA Significantly Improved Overall Survival and Progression-Fre..
01/17 MERCK AND : Keytruda aces another lung cancer study
01/17 MERCK AND COMPANY : Today’s Research Reports on Stocks to Watch: Bristol-Myers S..
More news
News from SeekingAlpha
01/19 Merck's Keytruda shows treatment effect in mid-stage liver cancer study
01/19 AstraZeneca's Lynparza OK'd in Japan for ovarian cancer; shares up 1% premark..
01/18 Big Biopharma in the red in early trade
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
Financials ($)
Sales 2017 40 228 M
EBIT 2017 13 722 M
Net income 2017 5 361 M
Debt 2017 13 208 M
Yield 2017 3,09%
P/E ratio 2017 29,95
P/E ratio 2018 19,67
EV / Sales 2017 4,47x
EV / Sales 2018 4,35x
Capitalization 167 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 66,9 $
Spread / Average Target 9,4%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.24%166 723
JOHNSON & JOHNSON5.20%394 704
NOVARTIS0.61%224 711
PFIZER2.65%220 487
ROCHE HOLDING LTD.-5.40%210 743
AMGEN8.11%136 174